We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+8.89%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$385M
AUM Growth
-$36.8M
Cap. Flow
-$9.14M
Cap. Flow %
-2.37%
Top 10 Hldgs %
72.83%
Holding
43
New
5
Increased
16
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$20.3M
2
INSM icon
Insmed
INSM
+$7.93M
3
VERV
Verve Therapeutics
VERV
+$4.58M
4
NTLA icon
Intellia Therapeutics
NTLA
+$3.84M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.51M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$18.4M
2
CYTK icon
Cytokinetics
CYTK
+$9.36M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.63M
4
YMAB
Y-mAbs Therapeutics
YMAB
+$6.4M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$2.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$80.7M 20.93%
7,648,268
– –
ITOS
2
DELISTED
iTeos Therapeutics
ITOS
$34.1M 8.85%
1,745,943
– –
INBX
3
DELISTED
Inhibrx, Inc. Common Stock
INBX
$31.7M 8.22%
1,286,435
+6,440
+0.5% +$189K
RPTX
4
DELISTED
Repare Therapeutics
RPTX
$24.1M 6.26%
1,639,849
– –
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$22.7M 5.89%
1,059,688
+9,688
+0.9% +$207K
QURE icon
6
uniQure
QURE
$3.38B
$21.3M 5.53%
+939,966
New +$20.3M
GERN icon
7
Geron
GERN
$970M
$20.5M 5.32%
8,466,981
+44,399
+0.5% +$99.5K
NTLA icon
8
Intellia Therapeutics
NTLA
$1.8B
$15.9M 4.12%
455,238
+80,829
+22% +$3.84M
VERV
9
DELISTED
Verve Therapeutics
VERV
$15.6M 4.06%
808,661
+172,869
+27% +$4.58M
RGNX icon
10
Regenxbio
RGNX
$638M
$14.1M 3.66%
621,372
+2,289
+0.4% +$51.7K
IOVA icon
11
Iovance Biotherapeutics
IOVA
$3.63B
$13.7M 3.56%
2,149,550
+449,550
+26% +$3.51M
PRVB
12
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$9.5M 2.46%
898,483
+158,139
+21% +$1.28M
INSM icon
13
Insmed
INSM
$25.9B
$8.2M 2.13%
+410,463
New +$7.93M
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.3B
$7.77M 2.02%
26,773
-17,974
-40% -$1.76M
HRMY icon
15
Harmony Biosciences
HRMY
$2.28B
$7.68M 1.99%
139,377
+2,597
+2% +$143K
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$7.38M 1.91%
194,181
+15,123
+8% +$520K
CRNX icon
17
Crinetics Pharmaceuticals
CRNX
$9B
$6.8M 1.76%
371,639
+6,929
+2% +$122K
TVTX icon
18
Travere Therapeutics
TVTX
$6.19B
$5.92M 1.54%
281,711
+5,251
+2% +$111K
HOWL icon
19
Werewolf Therapeutics
HOWL
$45.8M
$4.9M 1.27%
2,388,011
– –
FOLD
20
DELISTED
Amicus Therapeutics
FOLD
$4.89M 1.27%
400,410
+7,464
+2% +$84K
AXSM icon
21
Axsome Therapeutics
AXSM
$10.4B
$4.01M 1.04%
+51,975
New +$3.11M
ARQT icon
22
Arcutis Biotherapeutics
ARQT
$2.99B
$3.88M 1.01%
262,069
+4,884
+2% +$85.3K
RVMD icon
23
Revolution Medicines
RVMD
$44.6B
$3.55M 0.92%
149,043
+3,002
+2% +$63.8K
GTHX
24
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.53M 0.92%
650,000
-206,798
-24% -$1.73M
TCRR
25
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.37M 0.87%
3,370,982
– –
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2022 Portfolio in Review

As of Q4 2022, MPM BioImpact held 43 positions worth $385M, down 8.7% from $422M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

MPM BioImpact's Q4 2022 filing shows 5 new, 16 increased, 4 reduced and 10 closed positions. Its largest new stake was uniQure: 939,966 shares worth $21.3M. The largest sale was Merus, an estimated $18.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q4 2022 buy was uniQure: 939,966 shares worth $21.3M.
  • MPM BioImpact added most to Verve Therapeutics in Q4 2022, an estimated $4.58M increase.
  • MPM BioImpact's biggest Q4 2022 reduction was Madrigal Pharmaceuticals, cutting an estimated $1.76M.
  • MPM BioImpact fully exited Merus in Q4 2022, selling an estimated $18.4M.
  • MPM BioImpact's ten largest holdings make up 73% of its $385M portfolio in Q4 2022.
  • MPM BioImpact opened 5 new positions and closed 10 in Q4 2022.
  • MPM BioImpact's portfolio value fell 8.7% quarter-over-quarter to $385M.

Based on MPM BioImpact's 13F filing for Q4 2022, filed 14 Feb 2023.